New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
0
1

Indoor Tanning Linked to Melanoma Among Young Women

Indoor tanning may explain why U.S. melanoma rates are rising faster for women than for men, according to new research.  
medscape.com
almost 4 years ago
Preview
2
36

Melanoma Skin Cancer - The Mount Sinai Hospital

Learn more about the #risk factors, #signs, stages and advanced #treatments for melanoma skin cancer. Visit our #Skin #Cancer Center at http://www.mountsinai.org/skincancer #infographic #Health #Medical #Medicine #treatment #HealthyTips #Wellness |Skin Cancer, Cancer and Infographic.  
uk.pinterest.com
almost 4 years ago
Preview
0
0

Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common types of non-melanoma skin cancer. Epidemiological studies have indicated that the incidence of non-melanoma skin cancers is higher in patients with rheumatoid arthritis than in the general population.1 2 Further concerns exist that immunosuppression contributes to an increased prevalence of these malignancies. Specifically, organ transplantation and the concomitant use of immunosuppressive agents is strongly associated with SCC and to a lesser extent with BCC.3 4 Tumor necrosis factor (TNF) inhibitors are the most commonly used biological immunosuppressive agents for treatment of rheumatoid arthritis. Pooled data from 74 randomized controlled trials showed that TNF inhibitors were associated with an increase in risk of non-melanoma skin cancer beyond the risk associated with rheumatoid arthritis alone.5 Several large observational studies have supported this finding,6 7 but others have not.8 9 …  
feeds.bmj.com
almost 4 years ago
Preview
0
0

Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common types of non-melanoma skin cancer. Epidemiological studies have indicated that the incidence of non-melanoma skin cancers is higher in patients with rheumatoid arthritis than in the general population.1 2 Further concerns exist that immunosuppression contributes to an increased prevalence of these malignancies. Specifically, organ transplantation and the concomitant use of immunosuppressive agents is strongly associated with SCC and to a lesser extent with BCC.3 4 Tumor necrosis factor (TNF) inhibitors are the most commonly used biological immunosuppressive agents for treatment of rheumatoid arthritis. Pooled data from 74 randomized controlled trials showed that TNF inhibitors were associated with an increase in risk of non-melanoma skin cancer beyond the risk associated with rheumatoid arthritis alone.5 Several large observational studies have supported this finding,6 7 but others have not.8 9 …  
feeds.bmj.com
almost 4 years ago
Preview
0
0

Skin Cancer More Deadly When Caught During Pregnancy

Melanoma may be even more dangerous when it's diagnosed in women during pregnancy or within a year of giving birth, a U.S. study suggests.  
medscape.com
almost 4 years ago
Preview
0
1

Pembrolizumab Now Approved for First Line in Melanoma

The cell programmed-death inhibitor pembrolizumab was more effective and less toxic in first-line treatment when compared with ipilimumab.  
medscape.com
almost 4 years ago
Preview
0
0

Systemic Therapy for Advanced Melanoma: Making the Right Choices CME/CE

This activity is intended for hematologists/oncologists, dermatologists, nurses, and other healthcare professionals involved in the care of patients with melanoma.  
medscape.org
almost 4 years ago
Preview
0
0

Emerging Concepts in the Management of Melanoma: Perspectives From SMR CME

: Reports from the SMR Meetings cover biology and insights into therapy for metastatic melanoma.  
medscape.org
almost 4 years ago
Preview
0
0

Pembrolizumab Not So Hot (Yet) for Breast Cancer

Checkpoint inhibition has been notably successful in melanoma, lung cancer, and other malignancies. The story about its use in breast cancer is developing.  
medscape.com
about 4 years ago
Preview
0
0

Oncology Exchange: New and Emerging Therapies for Metastatic Melanoma CME

This activity was developed for community-based oncologists, dermatologists, dermatologic surgeons, and other healthcare professionals involved in the care of patients with melanoma.  
medscape.org
about 4 years ago
Preview
0
2

A New Dermoscopic Algorithm for Diagnosing Acral Melanoma

The authors present a dermoscopic prediction model for the differentiation between early acral melanomas and acral naevi.  
medscape.com
about 4 years ago
Preview
0
0

Research is the future: get involved

Research and journalism can work together to achieve better outcomes for patients. In 2013 The BMJ published a feature on the fashionable practice of sentinel node biopsy in people with malignant melanoma (doi:10.1136/bmj.e8645). The journalist Ingrid Torjesen reported that follow-up data from a key clinical trial had not been published. Her article prompted a commentary in the British Journal of Dermatology raising doubts about the benefits of sentinel node biopsy (doi:10.1111/bjd.12487). When the long awaited data were eventually published in the New England Journal of Medicine last year (doi:10.1056/NEJMoa1310460), specialty journals ran further critical comment.  
feeds.bmj.com
about 4 years ago
Preview
0
0

New Therapies Needed for Leptomeningeal Carcinomatosis

Leptomeningeal carcinomatosis is a highly fatal complication of melanoma and other cancers, and new therapies have failed to improve prognosis.  
medscape.com
about 4 years ago
Preview
0
1

FDA Okays First-line Nivolumab Alone in Melanoma

Nivolumab, already approved as a first-line treatment for advanced melanoma in combination with ipilimumab, is now approved as a monotherapy too.  
medscape.com
about 4 years ago
Preview
0
0

'Real-World' Melanoma Treatment Patterns Similar to Trials

Treatment patterns in the clinic reflect those of clinical trials, but why are some patients are not receiving a full treatment cycle?  
medscape.com
about 4 years ago
Preview
0
0

New Strategies but Modest Benefit in Uveal Melanoma

New therapies being tried in uveual melanoma include combination everolimus, pasireotide long-acting release, and the MEK inhibitor trametinib.  
medscape.com
about 4 years ago
Preview
0
0

Gynecologic Melanoma Different From Cutaneous Counterpart

Histochemical and molecular differences set gynecologic mucosal melanoma apart from the otherwise phenotypically identical cutaneous type.  
medscape.com
about 4 years ago
Preview
0
8

Anti-PD-1 Agents Superior to Others in Advanced Melanoma

Outcomes were better with anti-PD-1 therapy than with conventional treatment or anti-CTLA-4 therapy, a new meta-analysis has demonstrated.  
medscape.com
about 4 years ago
Preview
0
7

Society for Melanoma Research (SMR) 2015 Congress

Society for Melanoma Research (SMR) 2015 Congress: Read clinically focused news coverage of key developments from SMR 2015.  
medscape.com
about 4 years ago
Preview
0
5

Acute Kidney Injury Linked to BRAF Inhibitors in Melanoma

Treatment with vemurafenib and dabrafenib was associated with acute renal toxicity in patients with melanoma, according to data from the FDA Adverse Event Reporting System.  
medscape.com
about 4 years ago